# A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

> **NCT07199777** · PHASE2 · NOT_YET_RECRUITING · sponsor: **SciNeuro** · enrollment: 60 (estimated)

## Conditions studied

- Diabetic Macular Edema
- DME

## Interventions

- **DRUG:** SNP318
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07199777
- **Lead sponsor:** SciNeuro
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199777, "A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07199777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*